Výsledky vyhledávání

Autor: D A, Handley, J, Morley, L, Vaickus

Publikováno v: Expert Opinion on Investigational Drugs. 7:2027-2041

Racemic salbutamol (racemic albuterol) ameliorates symptoms of asthma by activating beta-adrenoceptors on nerve, smooth muscle and inflammatory cells within the airways. Racemic salbutamol comprises equal proportions of 2 isomers: (S)-salbutamol and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fafff225561747f9de244e6d19b2906
https://doi.org/10.1517/13543784.7.12.2027

Zobrazit plný text záznamu

Monoclonal antibodies and chemiluminescence immunoassay for detection of the surface protein of human T-cell lymphotropic virus

Autor: L D Papsidero, R P Dittmer, B J Poiesz, L Vaickus

Publikováno v: Journal of Clinical Microbiology. 30:351-358

Monoclonal antibodies (MAbs) raised against human T-cell lymphotropic virus type I (HTLV-I) recognized five distinct antigenic domains of viral env gene-encoded proteins. By using recombinant env proteins and synthetic peptides as mapping antigens, i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a8e9722bb0a952baf492cf9dbab6015e
https://doi.org/10.1128/jcm.30.2.351-358.1992

Zobrazit plný text záznamu

Interleukin-2 Lymphokine-Activated Killer Cell Therapy of Non-Hodgkinʼs Lymphoma and Hodgkinʼs Disease

Autor: Z. P. Bernstein, L. Vaickus, N. Friedman, M. H. Goldrosen, H. Watanabe, R. Rahman, S. G. Arbuck, J. Sweeney, D. Vesper, E. D. Henderson, J. Zeffren, R. A. Dennin, D. Levitt, K. A. Foon

Publikováno v: Journal of Immunotherapy. 10:141-146

We conducted a phase II study utilizing interleukin-2 (IL-2) with lymphokine-activated killer (LAK) cells as therapy for non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD). IL-2 was given at a fixed dose of 3 x 10(6) U/m2/day administered as a 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3269a3df0a39215363780d3e78d19e9a
https://doi.org/10.1097/00002371-199104000-00008

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity

Autor: N J, Meropol, M, Porter, L E, Blumenson, M J, Lindemann, R P, Perez, L, Vaickus, G M, Loewen, P J, Creaven, K A, Wilkes, M A, Giedlin, M A, Caligiuri

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 2(4)

We aimed to determine the toxicity and immunological effects of daily s.c. administered low-dose interleukin (IL) 2. Adult cancer patients received a single daily s.c. injection of IL-2 as outpatients for 90 consecutive days. Cohorts of four to nine

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::d6d7ae3130cbaacab40c6d676c6a1e96
https://pubmed.ncbi.nlm.nih.gov/9816217

Zobrazit plný text záznamu

Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen

Autor: K A, Foon, A R, Oseroff, L, Vaickus, S J, Greenberg, D, Russell, Z, Bernstein, S, Pincus, H, Köhler, B K, Seon, E, Tahaoglu

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 1(11)

We generated an IgG1 murine monoclonal anti-idiotype antibody (Ab2) to a highly restricted T-cell antigen designated glycoprotein (gp) 37 that is found on T-cell malignancies but not on normal cells. gp37 is identified by the murine monoclonal antibo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1665c8190f84f444f7c87dc3a764ca36
https://pubmed.ncbi.nlm.nih.gov/9815923

Zobrazit plný text záznamu

Autor: J D, Wilkes, P, Fidias, L, Vaickus, R P, Perez

Publikováno v: Cancer. 76(8)

Malignancy-related pericardial effusions may represent a terminal event in patients with therapeutically unresponsive disease. However, select patients with malignancies sensitive to available therapies may achieve significant improvement in palliati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b96736968b0e80d065ad2b0a43d9c39
https://pubmed.ncbi.nlm.nih.gov/8620412

Zobrazit plný text záznamu

Carboplatin for small cell lung cancer: progress toward greater efficacy and reduced toxicity

Autor: D, Raghavan, R, Perez, P, Creaven, H, Takita, G, Loewen, L, Vaickus

Publikováno v: Seminars in oncology. 21(3 Suppl 6)

Small cell lung cancer, an aggressive malignancy characterized by early dissemination, is highly responsive to radiotherapy and cytotoxic chemotherapy. Since the introduction of combined-modality regimens that incorporate both radiotherapy and chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::9f5845da0da4f7ffb03f2d81b9d30e05
https://pubmed.ncbi.nlm.nih.gov/8052868

Zobrazit plný text záznamu

Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR

Autor: D. Doty, M. Rosenzweig, L. Vaickus, J. Guild, M. Slavonic, J. Ponte, P. Ponath, I. Apostolou

Publikováno v: Journal of Clinical Oncology. 28:e13028-e13028

e13028 Background: Glucocorticoid-induced tumor necrosis factor receptor (GITR) is expressed on several cell types, including regulatory and effector T cells, B cells, NK cells, and antigen-presenting cells. In murine models, our agonistic anti-mouse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c36413ea3e7176829a89cdd09f62a0f3
https://doi.org/10.1200/jco.2010.28.15_suppl.e13028

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání